Key points are not available for this paper at this time.
These data suggest that pharmacological inhibition of NOX4 may have broad applicability for stromal targeting across cancer types.
Share your take
Add a clinician perspective alongside expert commentary.
Hanley et al. (Thu,) studied this question.